The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
A new initiative to contribute to enhancing drug discovery capabilities in the field of gene and cell therapy in Japan
Konieczny has served as Interim CEO since April 2024
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
New Phase II data show vast majority of patients experiencing no relapses or disability progression
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Vimta Labs through its diagnostic and pathological services business has recorded a revenue of Rs. 30 crores during FY 2024 and Rs. 7 crores in Q1 FY 2025
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Subscribe To Our Newsletter & Stay Updated
